^
Association details:
| Biomarker: | KIT fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
Excerpt:
A mutation, translocation, or fusion in the KIT gene in the patient's tumor felt to be potentially sensitive to tyrosine kinase inhibition.
Trial ID:
